Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results


SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (“Selected TIL”) therapy, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates.

Go here to read the rest:
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

Related Posts